Trial
NCT04402073
Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators
—
Condition
Medulloblastoma
Intervention
Sonidegib
Why stopped
Poor accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-23